Core Insights - The beauty industry is undergoing a significant transformation as consumers prioritize product ingredients and efficacy over marketing narratives and brand stories [1][2] - The competition among companies is shifting from traditional marketing to a focus on scientific validation and technical authority, particularly regarding core ingredients [1][3] Group 1: Industry Dynamics - The battle for defining the "ingredient king" is exemplified by the prolonged conflict between Huaxi Biological and Juzhi Biological over recombinant collagen, highlighting the industry's shift towards scientific discourse [1][2] - Companies are increasingly engaged in disputes over intellectual property and scientific narratives, as seen in the conflict between medical company Aierfu and skincare brand Zhanmeiya, which revolves around the storytelling of scientific advancements [3] Group 2: Market Competition - The competition for established, cash-generating scientific products is illustrated by the dispute between Shuiyang Co. and Ruoyu Chen over the agency rights for the Spanish brand "Mestique," which has shown remarkable growth in the Chinese market [5][6] - The financial performance of companies varies significantly, with some experiencing revenue growth alongside increased R&D spending, while others face declining revenues despite high R&D investments [6][7] Group 3: Consumer Behavior - A significant shift in consumer preferences is noted, with 58.8% of consumers prioritizing product ingredients in their purchasing decisions, indicating a growing demand for transparency and efficacy [15][21] - The rise of the "ingredient party" has led to increased scrutiny of product claims, pushing companies to provide credible testing reports and validate their ingredients [15][21] Group 4: Future Trends - The beauty industry's future is marked by a "scientific arms race," with brands striving to establish their authority in scientific research and ingredient validation [8][16] - Companies are exploring unique natural ingredients and integrating skincare with makeup, reflecting a trend towards holistic beauty solutions [20][21]

Group 1 - The medical beauty sector increased by 0.4% on January 12, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] - The trading volume and turnover for Ai Meike were 44,900 shares and 6.76 billion yuan, respectively [1] Group 2 - The net outflow of main funds in the medical beauty sector was 50.50 million yuan, while retail funds saw a net inflow of 24.49 million yuan [1] - The detailed fund flow for individual stocks showed significant net outflows for *ST Meigu and Jinbo Biological, with net outflows of 7.42 million yuan and 39.56 million yuan, respectively [2] - Ai Meike experienced a net outflow of 34.20 million yuan from main funds, indicating a 5.06% decrease in net shareholding [2]

Group 1 - The core viewpoint of the article emphasizes the growing importance of ESG (Environmental, Social, and Governance) as a key metric for high-quality corporate development and a vital link between corporate value and social value [1][2] - The "2025 China ESG Top 100" list was released by Sina Finance, evaluating over 5,000 A-share listed companies and mainland companies listed in Hong Kong using 18 industry-specific ESG evaluation models and over 150 ESG indicators [1][2] - The list serves as a benchmark for industry development and provides valuable decision-making references for investors [1][2] Group 2 - Huaxi Biological was recognized for its outstanding ESG performance, ranking 88th on the "2025 China ESG Top 100" list, highlighting its commitment to sustainable development practices [2] - The release of the list is seen as an authoritative recognition of the sustainable practices of the listed companies and promotes the core values of ESG across the industry [2] - Companies are encouraged to integrate ESG principles into their strategic planning, operations, and supply chain collaboration to achieve a symbiotic relationship between commercial and social value [2] Group 3 - The top companies in the "2025 China ESG Top 100" list include major players such as China Construction Bank, China Mobile, Agricultural Bank of China, Tencent, and Bank of China, all receiving a five-star rating [4][5] - The list reflects a diverse range of industries, including finance, telecommunications, information technology, and renewable energy, showcasing the broad commitment to ESG practices across sectors [4][5][6] Group 4 - The Sina Finance ESG Rating Center is the first Chinese professional platform for ESG information and ratings, aiming to promote sustainable development and responsible investment [11] - The center is focused on establishing ESG evaluation standards suitable for China's unique characteristics and advancing the development of ESG investment in the asset management industry [11]

Group 1 - The medical beauty sector increased by 2.39% on January 9, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] - Key stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 149.91, up 2.69%, and *ST Meigu closing at 3.34, down 1.18% [1] Group 2 - The medical beauty sector saw a net inflow of 192.35 million yuan from main funds, while retail investors experienced a net outflow of 3038.42 million yuan [1] - Specific stock fund flows indicated that Huaxi Biological had a main fund net inflow of 11.58 million yuan, while Ai Meike had a net outflow of 3941.60 million yuan from retail investors [2] - *ST Meigu had a significant net outflow of 1095.28 million yuan from main funds, but a net inflow of 956.07 million yuan from retail investors [2]

Core Viewpoint - The major shareholder of Hyaluronic Acid giant, Huaxi Biological, has reduced its stake, indicating potential shifts in shareholder dynamics and company performance concerns [1][3]. Shareholder Actions - Guoshou Chengda reduced its holdings by 4.85 million shares, representing 1.01% of the total shares, leaving it with 24.08 million shares, or approximately 5.00% of the total share capital [1][3]. - The reduction was part of a planned divestment, with a total of up to 9.63 million shares (2.00% of total shares) expected to be sold between November 26, 2025, and February 23, 2026 [3]. Company Performance - Huaxi Biological has faced declining profits since 2023, with revenue and net profit dropping by 4.45% and 38.97% respectively in 2023 [5]. - The functional skincare segment saw a revenue decrease of 18.45%, contributing to 61.84% of the main business income [5]. - In 2024, the company rebranded its personal health consumer products line to "Skin Science Innovation Transformation," but still reported a revenue decline of 11.61% to 5.371 billion CNY and a net profit drop of 70.59% to 174 million CNY [5]. Market Position - The company's stock price has seen significant declines, with a market value dropping from a peak of over 100 billion CNY to 21.892 billion CNY as of January 9, 2026 [6]. - The stock price has decreased by 12.71%, 50.48%, 23.34%, and 14.24% from 2022 to 2025 [6].

Group 1 - The core point of the news is that Shanghai Jiakai Biological Co., Ltd. has responded to the first round of inquiry from the Beijing Stock Exchange regarding compliance issues related to equity changes, control stability, product quality risks, and the sustainability of performance growth [2][4] Group 2 - Jiakai Biological was established in 2015 and focuses on the research, production, and sales of cosmetic functional raw materials, primarily used in skincare, masks, and hair care products [4] - The company plans to raise 310 million yuan through its IPO, which will be fully allocated to a project for annual production of 50 tons of functional plant extracts [4] - The company has seen significant valuation growth, from 3 billion yuan in 2020 to 24.7 billion yuan in 2025, reflecting an increase of over 7 times in five years [5] Group 3 - Revenue figures for Jiakai Biological from 2023 to the first three quarters of 2025 are 218 million yuan, 242 million yuan, and 195 million yuan, with year-on-year changes of 19.1%, 11.46%, and 7.91% respectively [5] - Net profit for the same period is 48 million yuan, 57 million yuan, and 47 million yuan, with year-on-year changes of -12.82%, 19.83%, and 16.91% respectively [5]

Core Viewpoint - Huaxi Biological (688363.SH) announced a share reduction by its major shareholder Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership) between November 26, 2025, and January 7, 2026 [1] Summary by Category Share Reduction Details - The reduction will be executed through centralized bidding and block trading, with 2,844,591 shares (0.59%) reduced via centralized bidding and 2,008,000 shares (0.42%) via block trading [1] - The total reduction amounts to 4,852,591 shares, representing 1.01% of the company's total share capital [1] Post-Reduction Shareholding - After the reduction, Guoshou Chengda will hold 24,083,913 shares of Huaxi Biological, which constitutes approximately 5.00% of the total share capital [1]

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining global attention in the health industry for its potential anti-aging, DNA repair, and metabolic regulation benefits, with significant regulatory advancements expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2][19]. Regulatory Environment - The global regulatory landscape for NMN is shifting from strict restrictions to cautious openness, with significant milestones achieved in countries like Japan, Canada, the US, and Australia [17][18]. - In China, NMN has been approved as a new cosmetic ingredient and is on the path to becoming a recognized health food, with the National Market Supervision Administration listing it for health food approval in April 2025 [17][18]. Market Demand - The aging population in China is driving the "silver economy," with projections indicating that the elderly population will grow from 320 million to 390 million between 2025 and 2030, creating a substantial market for anti-aging products [19]. - The younger generation, particularly those born in the 1990s, is increasingly aware of anti-aging needs, further boosting market demand for NMN products [19]. Technological Advancements - Innovations in synthesis, quality testing, and delivery methods are driving the NMN industry forward, with full enzyme methods significantly enhancing production efficiency and reducing costs [21][22]. - The transition from chemical synthesis to full enzyme methods is leading to higher purity and environmental sustainability in NMN production [10][12]. Application Areas - NMN is primarily used in health supplements and cosmetics, with the health supplement market accounting for nearly 90% of its applications, including anti-aging and immune support products [24][28]. - Future applications are expected to expand into pet nutrition, medical health, and agricultural technology, opening new growth avenues for the industry [24][28]. Market Size and Growth - The NMN market in China is projected to exceed 3 billion yuan by 2025, driven by increasing regulatory clarity and expanding applications in various sectors [28][32]. - The market has been growing steadily since 2020, with significant penetration into health supplements and cosmetics [28][32]. Sales Channels - NMN products are primarily sold through cross-border e-commerce and private channels, with cross-border e-commerce accounting for 60% to 70% of market share [35][34]. - Brand private channels are also showing strong performance, capturing about 30% of the market share [35]. Certification and Standards - The "blue hat" certification for health foods in China represents the highest standard for NMN products, indicating safety and compliance [37]. - Achieving this certification could significantly reshape the market landscape for NMN products in China [37]. Future Prospects - The NMN industry is poised for growth, with regulatory breakthroughs expected to enhance market opportunities, particularly in the cosmetics sector [51]. - The potential for NMN in pet nutrition, medical health, and agricultural technology is also being explored, indicating a broadening of its application scope [53][56][58].

Core Viewpoint - Huaxi Bio announced a shareholding change involving its major shareholder Guoshou Chengda, which will not trigger a mandatory takeover bid and will not alter the control of the company [2] Group 1: Shareholding Change - Guoshou Chengda plans to reduce its shareholding as per the announcement made on November 5, 2025, regarding the share reduction plan [2] - After the shareholding change, Guoshou Chengda will hold 24,083,913 shares, representing approximately 5.00% of the total share capital of Huaxi Bio [2] - Guoshou Chengda does not have any concerted action parties, ensuring that the control structure of the company remains unchanged [2]

华熙生物科技股份有限公司 简式权益变动报告书 上市公司名称：华熙生物科技股份有限公司 股票上市地点：上海证券交易所 股票代码：688363 信息披露义务人名称：国寿成达（上海）健康产业股权投资中心（有限合伙） 通讯地址：北京市朝阳区东三环中路 5 号财富金融中心 67 层 注册地址：中国（上海）自由贸易试验区银城路 88 号 39 楼 06 单元 邮政编码：100020 股份变动性质：股份减少及持股比例减少至 5% 签署日期：2026 年 1 月 8 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公司信 息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"《准则 15 号》"） 及相关的法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》、《收购办法》、《准则 15 号》的规定，本报告书已全面 披露了信息披露义务人在华熙生物科技股份有限公司中拥有 ...